# GLP-1 and Semaglutide Marketing: The Regulatory Minefield Every Weight Loss Clinic Needs to Navigate

GLP-1 and semaglutide marketing is the fastest-growing FDA enforcement category in healthcare. Here's the stack of rules weight loss clinics face: drug identity, compounding rules, off-label indication, outcome claims, and before/after photo compliance.

By RegenCompliance Editorial (FDA/FTC compliance desk). Published 2026-04-17. Reading time 11 minutes.
Canonical page: https://regencompliance.ai/blog/glp-1-semaglutide-marketing-compliance

No healthcare specialty has seen a faster increase in FDA and FTC enforcement over the last 18 months than weight loss clinics marketing GLP-1 receptor agonists - semaglutide, tirzepatide, liraglutide, and their compounded variants. The regulatory environment around GLP-1 is the most complex in healthcare advertising today because it overlays five distinct issues at once.

This post walks through that five-layer stack: drug identity, compounding rules, off-label use, outcome claims, and before/after photo compliance. If you run a weight loss or metabolic clinic marketing GLP-1 products, each layer has to be addressed separately.

Why this specialty is a regulator magnet

GLP-1 marketing combines three aggravating factors for regulators at once: (1) very high consumer demand driving aggressive marketing behavior across clinics; (2) branded drug identity confusion between approved products and compounded versions; (3) an outcome (weight loss) that is both a health goal and a commercial claim, with clearly substantiable and clearly unsubstantiable versions sitting side-by- side in the same marketing copy. The FDA and FTC are both active.

## Layer 1: Drug identity and name use

Novo Nordisk markets semaglutide under three brand names: Ozempic (type 2 diabetes), Wegovy (chronic weight management), and Rybelsus (oral type 2 diabetes). Eli Lilly’s tirzepatide is branded Mounjaro (diabetes) and Zepbound (weight management). Using the branded name in your clinic’s marketing triggers trademark and regulatory issues.

### The rules at a glance

- **Never market a branded drug you don’t dispense.** Using “Ozempic” in your copy implies you’re providing Ozempic.
- **Never imply a compounded product is the branded product.** Semaglutide compounded at a 503A or 503B pharmacy is NOT Ozempic. FDA treats conflating the two as a misbranding issue.
- **Use the generic molecule name when describing compounded products.** “Compounded semaglutide” is factually accurate and doesn’t step on trademark.

Non-compliant

“Affordable Ozempic weight loss - $299/mo.”

Compliant alternative

“Medically supervised semaglutide weight loss program, using compounded semaglutide prepared by a state-licensed compounding pharmacy. This is not FDA-approved Ozempic or Wegovy.”

Why: Brand-name confusion is a federal issue on two tracks (FDA misbranding + Lanham Act trademark). The compliant version is explicit about the compounded status and the non-FDA-approved nature of the program.

## Layer 2: Compounding rules

The FDA allows compounded versions of drugs under [specific circumstances](https://www.fda.gov/drugs/human-drug-compounding/human-drug-compounding-laws) (503A for patient-specific prescriptions; 503B for outsourcing facilities). Compounded semaglutide marketing has its own set of FDA concerns:

- **Drug-shortage status:** Compounding of a drug on the FDA shortage list is permitted under specific rules; outside the shortage list, there are stricter constraints.
- **Marketing to the general public:** 503A compounding is patient-specific and based on an individual prescription. Marketing “come get semaglutide” to the public blurs this line and is an FDA enforcement target.
- **Product composition:** Compounded products may include additives (B12, B-complex, etc.) that are NOT present in the branded drug. Marketing these as “the same as Ozempic, plus extras” is false equivalence.

Non-compliant

“Our exclusive semaglutide+B12 formula - more effective than Ozempic.”

Compliant alternative

“A semaglutide formulation compounded to your individual prescription. Some programs include additional vitamin B12; this is an additive, not an FDA-evaluated enhancement to efficacy.”

Why: Never claim a compounded variant is “more effective” than the branded drug without head-to-head substantiation (which does not exist). Disclose additives as additives, not as efficacy enhancers.

## Layer 3: Off-label indication use

Semaglutide is FDA-approved for type 2 diabetes (Ozempic) and chronic weight management in patients meeting specific BMI criteria (Wegovy). Marketing semaglutide for weight loss in patients who don’t meet the Wegovy criteria is off-label use.

Off-label prescribing is legal for licensed physicians. Off-label *marketing* has significantly tighter rules. A clinic marketing semaglutide for weight loss without specifying the indication criteria is effectively promoting an unapproved use to the general public.

Non-compliant

“Semaglutide weight loss program - lose 15% of your body weight in 6 months.”

Compliant alternative

“Medically supervised GLP-1-based weight loss program. A physician consultation will determine whether GLP-1 therapy is appropriate based on your BMI, medical history, and weight loss goals. FDA-approved indications for weight management apply to specific patient populations.”

Why: Don't publish outcome-specific weight-loss claims to the general public. Route the clinical decision to the physician consultation and flag that FDA-approved indications are population-specific.

## Layer 4: Outcome claims

The weight loss industry has decades of FTC enforcement history around specific language. The agency has settled multiple cases against weight loss marketers for unsubstantiated claims including:

- Specific-pound or specific-percentage claims without substantiation.
- Before-and-after photo galleries implying typical outcomes.
- Testimonial-based outcome claims without typicality disclosure.
- “Guaranteed” weight loss language.
- Comparative claims (“better than diet and exercise”).

The FTC doesn’t care that GLP-1 drugs *do* produce weight loss in clinical trials. The enforcement theory is about how the claim is presented in marketing - whether it’s substantiated for this specific product, this specific population, and this specific clinical context. The [FTC Health Products Compliance Guidance](https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance) covers the substantiation standard for health-outcome claims.

Non-compliant

“Lose up to 30 lbs in 3 months, guaranteed.”

Compliant alternative

“Weight loss outcomes on GLP-1 therapy vary significantly by patient. In clinical trials of FDA-approved semaglutide for chronic weight management, the average weight loss was approximately 15% of body weight over 68 weeks in patients meeting specific criteria. Your results will depend on your starting point, adherence, and medical history.”

Why: Replace the outcome guarantee with honest clinical-trial-based language, specifying the population and timeframe. Long, specific, factual - and defensible.

## Layer 5: Before-and-after photos

Before-and-after weight loss photos are the most regulated visual format in healthcare marketing. The FTC Endorsement Guides govern this entire category. See [the before-and-after photos deep dive](https://regencompliance.ai/blog/before-after-photos-compliance) for the full protocol. For GLP-1 specifically:

- **Typical-experience disclosure required** on every photo presented as representative.
- **Time frame must be disclosed.** “Results in 90 days” requires that both photos were taken 90 days apart.
- **Patient consent documentation** must be retained.
- **Diet-and-exercise qualifier:** GLP-1 trial results assumed adherence to diet and exercise guidelines. Photos without that disclosure overclaim the drug’s solo contribution.

For the testimonial and typical-experience disclosure rules that govern GLP-1 outcome content, see the [FTC Endorsement Guides 2023 update](https://regencompliance.ai/blog/ftc-endorsement-guides-2023-update). For compounding-specific compliance detail, see [GLP-1 compounded marketing compliance 2026](https://regencompliance.ai/blog/glp-1-compounded-marketing-compliance-2026).

## Social media and platform policy specifics

Meta, TikTok, and Google have all tightened their healthcare ad policies specifically around GLP-1 marketing in 2024-2025. Platform-level rejection happens before any regulator notices, but platform violations are often the evidence a regulator uses to build a case.

- **Meta / Instagram:** Weight loss claims with specific numerical outcomes are typically rejected. Testimonials with dramatic transformations often trigger policy review.
- **TikTok:** Healthcare products including GLP-1 are on a restricted category list. Brand-name drug references in organic content (not just ads) have triggered video removal.
- **Google Ads:** Prescription drug advertising is heavily restricted and typically requires certification (LegitScript for pharmacy-related advertising). Weight loss claims face additional scrutiny.

## What a compliant GLP-1 program page looks like

1. **Landing hero:** “Medically supervised weight loss program featuring GLP-1 therapy.” No brand names, no outcome numbers, no guarantees.
2. **Program description:** Consultation process, BMI/ medical-history screening, prescription basis, follow-up cadence.
3. **What GLP-1 is:** Educational content on the drug class. Disclose clearly if you use compounded semaglutide.
4. **Who it’s for:** “A physician consultation determines whether GLP-1 therapy is appropriate for you.” Not “suitable for anyone who wants to lose weight.”
5. **Expected outcomes section:** Cite clinical-trial ranges with population and timeframe qualifiers. Individual- variation disclosure prominent.
6. **Risks:** Standard side-effect profile. Honest risk disclosure is both legally protective and trust-building.
7. **Testimonials (if any):** Subjective-experience language, typical-experience disclosure, substantiation file.
8. **Pricing:** Disclose compounded vs branded. Don’t position compounded as a “deal” on the branded drug.

GLP-1 rules are in the scanner

RegenCompliance includes GLP-1-specific rules covering brand-name misuse, compounded-product claims, off-label language, outcome- guarantee triggers, and typical-experience disclosure failures on weight-loss testimonials. Pre-publish scanning catches these before they’re platform-rejected or regulator-reviewed. [Try a free scan](https://regencompliance.ai/demo).

Key Takeaways

- GLP-1 marketing is the fastest-growing FDA enforcement category; five distinct regulatory layers apply simultaneously.
- Never use brand names (Ozempic, Wegovy, Mounjaro, Zepbound) in marketing for products you don't dispense, or to describe compounded versions.
- Compounded semaglutide is not FDA-approved semaglutide. Market the two separately, with explicit disclosure.
- Off-label marketing to the general public is tightly restricted even when off-label prescribing is legal. Route clinical decisions to the physician consultation.
- Before-and-after weight loss photos require time-frame disclosure, typical-experience disclosure, consent documentation, and diet/exercise qualifier.

---

RegenCompliance is FDA/FTC compliance scanning software for healthcare marketing, operated by Regen Portal LLC. Educational compliance tool, not legal advice. Not affiliated with the FDA or FTC. Contact: support@regencompliance.ai. Full site index for AI agents: https://regencompliance.ai/llms.txt